

Poland: 4Q GDP drop confirmed; 2020 fall a tad shallower

The GDP drop in 4Q20 was confirmed at 2.8% year-on-year (-0.7% quarter-on-quarter after seasonal adjustment). For the whole of 2020, GDP in Poland contracted by 2.7% YoY, a little better than the 2.8% fall initially estimated by the statistics office



Source: Shutterstock

-2.8%

GDP in 4Q20 (YoY)

In line with the flash estimate

As expected

The structure of 4Q20 GDP is broadly in line with our estimates. The decline in investment deepened to -10.9% YoY from -9% in 3Q20. Private consumption fell by 3.2% YoY vs. 0.4% growth in 3Q20. Surprisingly, the contribution to GDP growth from net exports was low, only +0.4ppts in 4Q20 compared to +1.7ppts in 3Q20. The balance of payments data suggested much

better results. It was offset by inventories (+0.6ppts to GDP in 4Q20 vs -2.3ppts in 3Q20). Both net exports and inventories are among the most frequently revised categories in the national accounts. Together, their contribution to GDP growth in 4Q20 was close to our estimates.

In terms of GDP creation, industry stands out. The real growth of value added in industry accelerated in 4Q20 to 4.8% YoY compared to +2.9% in 3Q20 and -11.8% in 2Q20.

We remain cautious about 1Q21 prospects. We are reiterating our forecast for a slight QoQ GDP contraction in this period. For the whole of 2021, we maintain our GDP growth forecast at 4.5% YoY, for now, although downside risks remain.

In January, industry reported good results. Construction and retail sales fared worse. With the easing of trade restrictions in February, sentiment improved in retail and services. Industrial sentiment continues to look relatively good.

But we are facing another wave of Covid-19 in Poland and we have to deal with the effects of prolonged restrictions in Europe. The vaccination in Europe still remains relatively slow, three times slower than in the USA. The low supply of vaccines has not yet been resolved. Yesterday, AstraZeneca announced that it will deliver only 40 million doses of vaccine to the EU in 1Q21, rather than the 80 million doses suggested in January.

Author

Rafal Benecki

Chief Economist, Poland

rafal.benecki@ing.pl

Disclaimer

This publication has been prepared by the Economic and Financial Analysis Division of ING Bank N.V. ("ING") solely for information purposes without regard to any particular user's investment objectives, financial situation, or means. *ING forms part of ING Group (being for this purpose ING Group N.V. and its subsidiary and affiliated companies)*. The information in the publication is not an investment recommendation and it is not investment, legal or tax advice or an offer or solicitation to purchase or sell any financial instrument. Reasonable care has been taken to ensure that this publication is not untrue or misleading when published, but ING does not represent that it is accurate or complete. ING does not accept any liability for any direct, indirect or consequential loss arising from any use of this publication. Unless otherwise stated, any views, forecasts, or estimates are solely those of the author(s), as of the date of the publication and are subject to change without notice.

The distribution of this publication may be restricted by law or regulation in different jurisdictions and persons into whose possession this publication comes should inform themselves about, and observe, such restrictions.

Copyright and database rights protection exists in this report and it may not be reproduced, distributed or published by any person for any purpose without the prior express consent of ING. All rights are reserved. ING Bank N.V. is authorised by the Dutch Central Bank and supervised by the European Central Bank (ECB), the Dutch Central Bank (DNB) and the Dutch Authority for the Financial Markets (AFM). ING Bank N.V. is incorporated in the Netherlands (Trade Register no. 33031431 Amsterdam). In the United Kingdom this information is approved and/or communicated by ING Bank N.V., London Branch. ING Bank N.V., London Branch is authorised by the Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. ING Bank N.V., London branch is registered in England (Registration number BR000341) at 8-10 Moorgate, London EC2 6DA. For US Investors: Any person wishing to discuss this report or effect transactions in any security discussed herein should contact ING Financial Markets LLC, which is a member of the NYSE, FINRA and SIPC and part of ING, and which has accepted responsibility for the distribution of this report in the United States under applicable requirements.

Additional information is available on request. For more information about ING Group, please visit <http://www.ing.com>.